The authors suggest that VDAC1 inhibition may be an underlying mechanism of drugs, such as sennoside A, a commonly used clinical laxative stimulant, for protecting mitochondria in HFD-induced hepatic steatosis in mice. This evidence concerns the gene VDAC1 and fatty liver disease.